Revolutionizing Drug Research: Viva Biotech’s 2024 Annual Results Show Remarkable Performance Boost with Cutting-Edge AI Technology Leading the Way to a New Era
Highlights of Annual Results for the Year Ended December 31, 2024
Revenue reached RMB1,986.7 million
Gross profit amounted to RMB687.4 million
Net profit recorded RMB222.0 million, a significant turnaround from a year ago
Adjusted Non-IFRS net profit recorded RMB314.6 million, a YOY increase of nearly 50.6%
SHANGHAI, March 27, 2025 /PRNewswire/ — On March 27, 2025, Viva Biotech Holdings (“Viva Biotech”, “the Group” or “the Company”, stock code: 1873.HK) announced that for the Group’s revenue during the Reporting Period achieved RMB1,986.7 million, gross profit amounted to RMB687.4 million and net profit recorded RMB222.0 million, a significant turnaround from a net loss of RMB99.8 million in the corresponding period of last year, mainly benefiting from the elimination of relevant financial adjustments due to the full repayment of convertible bonds, and an increase in adjusted non-IFRS net profit to RMB314.6 million from RMB208.8 million in the corresponding period of last year, representing an increase of nearly 50.6% as compared to last year, which was mainly attributable to an increase in operating profit margin driven by the recovery of CRO business growth and the improving operational efficiency in 2H2024, as well as the recognition of investment income from milestone payments received by the Group during the year.
In the rapidly-evolving landscape of pharmaceutical research and development, innovation is key to success. Viva Biotech’s impressive performance for the year ended December 31, 2024, highlights the company’s commitment to leveraging cutting-edge AI technology to revolutionize drug research. With revenue exceeding RMB1.9 billion and a significant increase in net profit, Viva Biotech is setting new standards in the industry.
The use of AI technology has enabled Viva Biotech to streamline the drug discovery process, leading to faster and more accurate results. By incorporating AI algorithms into their research, Viva Biotech has been able to identify potential drug candidates with higher success rates, ultimately reducing time and costs associated with traditional methods.
Furthermore, the company’s focus on operational efficiency and growth in the CRO business segment has contributed to their financial success. With a sharp increase in adjusted non-IFRS net profit, Viva Biotech is positioned for continued growth and innovation in the coming years.
How will this affect you?
For individuals, the impact of Viva Biotech’s advancements in drug research means a potential increase in the availability of innovative treatments and medications. With AI technology leading the way, there is the possibility of more efficient drug development processes, resulting in faster access to life-saving therapies.
How will this affect the world?
On a global scale, Viva Biotech’s progress in revolutionizing drug research has the potential to transform the pharmaceutical industry. By demonstrating the effectiveness of AI technology in advancing drug discovery, other companies may follow suit and adopt similar innovative approaches. This could lead to a shift towards more efficient and effective methods of developing new medications, ultimately benefiting patients worldwide.
Conclusion
In conclusion, Viva Biotech’s remarkable performance in 2024 is a testament to the power of innovation in drug research. By harnessing the potential of cutting-edge AI technology, the company has achieved significant financial success and is paving the way for a new era in pharmaceutical development. With a focus on efficiency, growth, and technology-driven solutions, Viva Biotech is poised to continue making a positive impact on the industry and advancing the field of healthcare for the betterment of society.
